ASH 2019 | Non-viral CAR-T engineering: CARCIK-CD19 for B-ALL
Logistical complexity and the high costs of manufacturing autologous viral products limit CAR T-cell availability. Chiara Magnani, PhD, University of Milano-Bicocca, Milan, Italy & Fondazione MBBM, Monza, Italy, discusses an ongoing phase I/II trial on donor-derived CD19 CAR cytokine-induced killer (CIK) cells engineered with a sleeping beauty (SB) transposon for relapsed B-cell acute lymphoblastic leukemia (B-ALL). The ongoing study demonstrates that SB-engineered CARCIK-CD19 cells can expand and persist in pediatric and adult B-ALL patients who have relapsed after hematopoietic stem cell transplantation (HSCT), with important implications for a non-viral technology. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
